JP2012529430A - 慢性腎臓疾患の治療方法 - Google Patents

慢性腎臓疾患の治療方法 Download PDF

Info

Publication number
JP2012529430A
JP2012529430A JP2012514218A JP2012514218A JP2012529430A JP 2012529430 A JP2012529430 A JP 2012529430A JP 2012514218 A JP2012514218 A JP 2012514218A JP 2012514218 A JP2012514218 A JP 2012514218A JP 2012529430 A JP2012529430 A JP 2012529430A
Authority
JP
Japan
Prior art keywords
nucleotide
modified
ckd
injury
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529430A5 (enExample
Inventor
エレナ フェインステイン
スヴェトラナ アダムスキー
シャイ アーリック
ブルース モリトリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, Represented By Department Of Veterans Affairs Washington Dc AS
Quark Pharmaceuticals Inc
Original Assignee
United States, Represented By Department Of Veterans Affairs Washington Dc AS
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States, Represented By Department Of Veterans Affairs Washington Dc AS, Quark Pharmaceuticals Inc filed Critical United States, Represented By Department Of Veterans Affairs Washington Dc AS
Publication of JP2012529430A publication Critical patent/JP2012529430A/ja
Publication of JP2012529430A5 publication Critical patent/JP2012529430A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012514218A 2009-06-08 2010-06-07 慢性腎臓疾患の治療方法 Pending JP2012529430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18493709P 2009-06-08 2009-06-08
US61/184,937 2009-06-08
US23538109P 2009-08-20 2009-08-20
US61/235,381 2009-08-20
PCT/US2010/037565 WO2010144336A2 (en) 2009-06-08 2010-06-07 Methods for treating chronic kidney disease

Publications (2)

Publication Number Publication Date
JP2012529430A true JP2012529430A (ja) 2012-11-22
JP2012529430A5 JP2012529430A5 (enExample) 2013-07-11

Family

ID=43309421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514218A Pending JP2012529430A (ja) 2009-06-08 2010-06-07 慢性腎臓疾患の治療方法

Country Status (8)

Country Link
US (2) US8637482B2 (enExample)
EP (2) EP2440214A4 (enExample)
JP (1) JP2012529430A (enExample)
CN (1) CN102458418B (enExample)
CA (1) CA2763537A1 (enExample)
DK (1) DK3276004T3 (enExample)
IL (1) IL216804A0 (enExample)
WO (1) WO2010144336A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9631170B2 (en) 2011-10-06 2017-04-25 University Of Wyoming Genetically inducible hydrogen peroxide resistance and production
ES2704855T3 (es) 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
CA2880290C (en) 2012-09-12 2020-10-27 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
US9546364B2 (en) 2013-03-15 2017-01-17 Carnegie Mellon University Synthetic lariat RNA for RNA interference
CN104073517A (zh) * 2013-03-28 2014-10-01 卫生部北京医院 p66Shc重组腺病毒载体及构建和应用
MX391220B (es) * 2013-05-14 2025-03-21 Metabolon Inc Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
SI3444349T1 (sl) * 2014-05-29 2021-07-30 Quark Pharmaceuticals, Inc. Postopki in sestavki za preprečevanje ishemične reperfuzijske poškodbe v organih
GB201413081D0 (en) * 2014-07-23 2014-09-03 Univ Birmingham Markers for AF
ES2627997B1 (es) * 2015-09-18 2018-05-21 Fundación Instituto De Investigación Sanitaria Fundación Jiménez Díaz Uso de una composición farmacéutica para la fabricación de un medicamento para el tratamiento y/o la prevención del daño renal agudo
EP4442200A3 (en) 2016-04-01 2024-12-04 Cardiac Pacemakers, Inc. Multi-disease patient management
WO2018027149A1 (en) * 2016-08-04 2018-02-08 University Of Miami Methods of treating alport syndrome
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11771113B2 (en) 2017-05-31 2023-10-03 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
CN116726173B (zh) * 2022-03-03 2025-09-23 浙江大学 Trpm2抑制剂的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084684A2 (en) * 2006-01-20 2007-07-26 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
JP2008514223A (ja) * 2004-09-28 2008-05-08 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
WO2008106102A2 (en) * 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2009044392A2 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US20090105173A1 (en) * 2006-03-09 2009-04-23 Elena Feinstein Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US20050032067A1 (en) 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
KR100414936B1 (ko) 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
NZ513402A (en) 1999-02-12 2003-06-30 Sankyo Co Novel nucleosides and oligonucleotide analogues
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
CA2467936C (en) 2001-11-21 2013-11-05 Mitsubishi Chemical Corporation Method of inhibiting gene expression
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
ES2576677T3 (es) 2003-03-21 2016-07-08 Roche Innovation Center Copenhagen A/S Análogos de ARN interfirientes cortos
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
US20080090765A1 (en) 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2008042012A1 (en) * 2006-10-05 2008-04-10 Rhode Island Hospital Compositions and methods for detecting and treating renal injury and inflammation
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
WO2009032915A2 (en) * 2007-09-06 2009-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arrays, kits and cancer characterization methods
US20090226547A1 (en) 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
WO2009116037A2 (en) * 2008-03-20 2009-09-24 Quark Pharmaceuticals, Inc. NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514223A (ja) * 2004-09-28 2008-05-08 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
WO2007084684A2 (en) * 2006-01-20 2007-07-26 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
US20090105173A1 (en) * 2006-03-09 2009-04-23 Elena Feinstein Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2008106102A2 (en) * 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2009044392A2 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014024720; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｕｒｏｌｏｇｙ Ｖｏｌ．１８１，　Ｎｏ．４　Ｓｕｐｐｌｅｍｅｎｔ, 20090429, ｐ．７４３ *
JPN6014024723; Ｊ　Ａｍ　Ｓｏｃ　Ｎｅｐｈｒｏｌ Ｖｏｌ．２０, 2009, １７５４-１７６４ *
JPN7015002769; 薬理学雑誌，　２００８，　Ｖｏｌ．１３１，　ｐ．３７-４２ *
JPN7015002770; 日腎会誌，　２００２，　Ｖｏｌ．４４（２），　ｐ．９４-１０１ *

Also Published As

Publication number Publication date
EP3276004A2 (en) 2018-01-31
CA2763537A1 (en) 2010-12-16
EP3276004B1 (en) 2020-03-18
WO2010144336A3 (en) 2011-02-03
IL216804A0 (en) 2012-02-29
WO2010144336A2 (en) 2010-12-16
US8637482B2 (en) 2014-01-28
CN102458418B (zh) 2015-09-16
US20140140922A1 (en) 2014-05-22
DK3276004T3 (da) 2020-04-06
EP2440214A2 (en) 2012-04-18
US20120141378A1 (en) 2012-06-07
EP2440214A4 (en) 2013-07-31
EP3276004A3 (en) 2018-03-14
CN102458418A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
JP2012529430A (ja) 慢性腎臓疾患の治療方法
JP7527437B2 (ja) 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
KR101409241B1 (ko) 탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법
TWI660731B (zh) 補體成分Ｃ５ ｉＲＮＡ組成物及其使用方法
CA2880290C (en) Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
JP2020533334A (ja) アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
KR20140092921A (ko) 트랜스티레틴（ＴＴＲ） 관련 질병을 치료하기 위한 ＲＮＡｉ 제제, 조성 및 그의 사용방법
PT2596807E (pt) Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
JP2023545502A (ja) リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
TW201629218A (zh) ＴＭＰＲＳＳ６ ｉＲＮＡ組成物及其用途方法
EP2802658A2 (en) Rnai agents to treat beta-catenin related diseases
CN113166760A (zh) 用于抑制angptl8的新型rna组合物和方法
WO2024187190A2 (en) Compositions and methods for inhibition of expression of inhibin subunit beta e (inhbe) genes
CN118853662A (zh) 一种靶向ANGPTL4的siRNA及其缀合物和用途
WO2014043292A1 (en) Double-stranded oligonucleotide molecules to p53 and methods of use thereof
CN101291948B (zh) 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
AU2012232948B2 (en) Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure and Other Diseases
EA048423B1 (ru) РНКи-АГЕНТЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (APOC3)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160404